vTv Therapeutics (NASDAQ:VTVT) Issues Earnings Results

vTv Therapeutics (NASDAQ:VTVT) released its quarterly earnings results on Wednesday. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44, Zacks reports. The company had revenue of $36.84 million for the quarter, compared to analyst estimates of $20.00 million.

vTv Therapeutics Trading Down 1.4%

Shares of NASDAQ:VTVT traded down $0.44 during mid-day trading on Wednesday, reaching $31.67. The company had a trading volume of 43,048 shares, compared to its average volume of 51,935. The firm has a market cap of $124.78 million, a price-to-earnings ratio of -9.45 and a beta of 0.26. The company’s 50-day moving average price is $35.88 and its 200-day moving average price is $33.94. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00.

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics in the 4th quarter worth approximately $221,000. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics in the 4th quarter worth approximately $731,000. Finally, Geode Capital Management LLC raised its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the period. Institutional investors own 17.51% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Roth Mkm assumed coverage on vTv Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $58.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Friday, March 27th. Finally, Evercore assumed coverage on vTv Therapeutics in a research note on Thursday, March 12th. They issued an “outperform” rating and a $44.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.